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Osteogenesis Imperfecta (OI) is a rare disorder of type 1 collagen with 13 
currently identified types attributable to inherited abnormalities in type 1 
collagen amount, structure, or processing.OI is a genetic disorder with 
skeletal, vascular, and soft tissue involvement with different clinical 
presentations. Since these patients need different surgical procedure in their 
lifetime, anesthesiologists are involved with their preoperative care and should 
be familiar with pathogenesis and anesthetic considerations of osteogenesis 
imperfecta. Here we represent a case of osteogenesis imperfecta, which was 
candidate for Video Assisted Thoracic Surgery (VATS) and review the 
literature. 
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Introduction 
Osteogenesis Imperfecta (OI) is a rare disorder 
of type 1 collagen with 13 currently identified types 
attributable to inherited abnormalities in type 1 
collagen amount, structure, or processing (1). OI 
comprises a heterogeneous group of disorders 
characterized by susceptibility to bone fractures 
ranging in severity from perinatal death to a subtle 
increase in fracture frequency (2). In addition to the 
skeletal phenotype, common additional extraskeletal 
manifestations include blue sclera, dentinogenesis 
imperfecta, vascular fragility, and hearing loss (1). 
Despite the low prevalence, the wide range of 
heterogeneity in features and advances in treatment 
makes OI a disease with special requirements and 
considerations. OI is a differential diagnosis for child 
abuse and different specialists, including orthopedist, 
pediatrist, dentists and even psychiatrists, are 
involved in treatment procedures to give the affected 
people a qualified life. Evidently, the role of 
anesthesiologists in this multidisciplinary approach 
may not be disregarded. Therefore, anesthesiologists 
should have proper knowledge about the variable 
genetic abnormalities and the consequent apparent 
and invisible features of OI, may affect the 
perioperative management. 
Case presentation 
A 44 years old man was brought to the 
emergency department after falling trauma. He was a 
known case of osteogenesis imperfecta diagnosed at 
the age of 18 years, made him disqualified for 
military service. He had a history of some long bone 
fractures in the past with minor trauma. His daily 
performance was acceptable without any respiratory 
or cardiac symptoms. He was homeless without any 
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relatives so there were limited data about family 
history. 
He weighed 70 kg, was conscious and his 
hemodynamic parameters were in normal range. He 
had blue sclera (Fig. 1) without vision impairments. 
The neck and jaw movements were normal with 
mallampati score of 2. Apart from poor dentition, the 
mouth and pharynx were normal. In lung auscultation 
there was decreased sound in the left hemithorax, 
congruent with pleural effusion on chest X-ray, 
besides a prominent aortic arch. Further X-ray studies 
demonstrated right scapula, humerus, tibia and knee 
fractures. Lab tests findings showed leukocytosis. The 
spirometry showed normal pattern. In 
echocardiography the ejection fraction was 60% and 
the pulmonary artery pressure was 28 mmHg with 
mild tricuspid regurgitation. Bone densitometry 
proved low bone marrow density in spine and hip. 
Chest tube insertion was planned in emergency 
department while the operation team prepared for 
unexpected hemorrhage and emergent thoracotomy 
and isogroup cross matched packed RBC was 
requested for probable event. After proper splinting 
and padding, the patient was transferred cautiously to 
operating room for visual assisted thoracoscopic 
surgery (VATS) to evaluate the source of 
hemothorax. The difficult airway equipments were 
prepared as well. The routine OR monitoring 
alongside temperature monitoring with 
nasopharyngeal probe attached and two large bore 
intravenous (IV) access number 18 and 16 were 
inserted under local anesthesia. He did not receive 
anything per os (NPO) during the last several hours. 
For surgical procedure all the intraoperative 
requirements for difficult intubation, malignant 
hyperthermia (MH), proper positioning and blood 
products were prepared beforehand. Total intravenous 
anesthesia (TIVA) was our choice for general 
anesthesia with full monitoring. The premedication 
included midazolam 2 mg, lidocaine 80 mg and 
fentanyl 150 µg via intravenous rout. The intubation 
was done with left side double lumen tracheal tube 
(DLT) number 39 after the induction of anesthesia 
with 140 mg propofol and 40 mg atracurium. 
Maintenance of anesthesia provided using propofol 
infusion to keep the depth of anesthesia in the range 
of 40 to 60 on cerebral state monitoring. Then the 
patient changed to right lateral decubitus position 
(LDP). During procedure there was about 150cc 
drainage of blood which caused no hemodynamic 
instability with no rising in temperature and end tidal 
CO2. At the end of VATS, DLT changed to 7.5 mm 
armored tracheal tube and orthopedic surgery began. 
Orthopedic procedure lasted about 3 hours with minor 
hemorrhage and at the end patient was awakened and 
extubated uneventfully. 
Discussion  
Osteogenesis imperfecta (OI), commonly 
called "brittle bone disease", is a genetic disorder 
characterized by increased bone fragility and 
decreased bone density due to quantitative and/or 
qualitative abnormalities of type I collagen (3). It is a 
variable condition with a range of clinical severities 
(4). Most of the cases of OI are inherited in autosomal 
dominant fashion with mutations in COL1A1 or 
COL1A2 genes. Over last few years, twelve genes for 
autosomal recessive OI have been identified (5). After 
2006, mutations were identified in the CRTAP, 
FKBP10, LEPRE1, PLOD2, PPIB, SERPINF1, 
SERPINH1, SP7, WNT1, BMP1, and TMEM38B 
genes, associated with recessive OI and mutation in 
the IFITM5 gene associated with dominant OI. 
Mutations in PLS3 were recently identified in 
families with osteoporosis and fractures, with X-
linked inheritance pattern. In addition to the genetic 
complexity of the molecular basis of OI, extensive 
phenotypic variability resulting from individual loci 
has also been documented (6). 
Osteogenesis imperfecta is classified into 11 
types to date, on the basis of their clinical symptoms 
and genetic components (7). For simplicity, the 
objectives of treatment can be reduced to three typical 
 
Figure 1. Blue Sclera. 
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situations: the lethal perinatal form (type II), in which 
the problem is survival at birth; the severe and 
moderate forms (types III-IX), in which the objective 
is 'autonomy' and the mild form (type I), in which the 
aim is to reach 'normal life' (8). The hallmark feature 
of OI is bone fragility, with susceptibility to fracture 
from minimal trauma, as well as bone deformity and 
growth deficiency. OI has multiple secondary 
features, including macrocephaly, blue sclera, 
dentinogenesis imperfecta, hearing loss, neurological 
defects (macrocephaly and basilar invagination) and 
cardiopulmonary complications (the major cause of 
mortality directly related to OI ) (9). 
Thanks to the genetic discoveries, 
bisphosphonates therapy and new surgical and 
rehabilitation method, a new era is developed for life 
span with rising quality in the population affected by 
this rare disease. As long as all surgical procedures 
need anesthesia, anesthesiologist should be aware of 
all aspects of OI which may interfere with anesthesia 
in perioperative period. Commonly encountered 
complications include a difficult airway, 
intraoperative bleeding due to platelet dysfunction, 
respiratory compromise due to skeletal deformity, and 
congenital cardiac anomalies (10). Cardiovascular 
effects are identifiable in childhood even in mild 
forms of OI. Aortic dilation is the predominant 
finding, while valvular abnormalities are infrequent 
(11). Cautious moving and positioning to avoid 
further fractures and meticulous monitoring of 
temperature due to the risk of malignant hyperthermia 
should not be underestimated. Proper preparation and 
preoperative assessment is important, as is the choice 
of anesthetic technique (10). Even though a direct 
relationship between OI and MH has not been proven 
(12), TIVA is the choice in OI to reduce the risk of 
MH during intraoperative period. Succinylcholine and 
volatile anesthetics are avoided in anesthesia 
management in OI.Cardiopulmonary assessment can 
reveal hidden problems especially in mild forms of OI 
and prevent further complications. 
Our patient, regarding to clinical manifestation, 
was in mild category. Since the airway was not 
compromised and the team was ready for difficult 
airway management including surgical tracheostomy, 
induction with IV anesthetic and nondepolarizing 
muscle relaxant was performed. The position and 
movements were carefully supervised by attendants. 
Certainly, close and full monitoring was the priority 
of our intraoperative care. 
Conclusion 
As a result of novel achievements in genetic 
and cellular studies and uprising hope to treat the 
patients with rare genetic disorders, anesthesiologists 
find themselves in new era of required skillful 
adaptable individuals who can work in dynamic 
situations (13-16). In addition to the fragile bones and 
probable difficult intubation, the risk of MH or 
probable hypermetabolic state, the risk of bleeding 
and cardiopulmonary complication should never be 
neglected in the shadow of urgent and emergent 
procedures. 
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